Page last updated: 2024-12-07
glycyl-glycyl-tyrosyl-arginine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
glycyl-glycyl-tyrosyl-arginine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not avail 12/92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 125825 |
| MeSH ID | M0209778 |
Synonyms (18)
| Synonym |
|---|
| ggyr |
| 70195-20-9 |
| (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid |
| gly-gly-tyr-arg |
| glycyl-glycyl-tyrosyl-arginine |
| n2-(n-(n-glycylglycyl)-l-tyrosyl)-l-arginine |
| l-arginine, n2-(n-(n-glycylglycyl)-l-tyrosyl)- |
| h-gly-gly-tyr-arg-oh |
| mfcd00076760 |
| AKOS030622944 |
| BS-17484 |
| (s)-2-((s)-2-(2-(2-aminoacetamido)acetamido)-3-(4-hydroxyphenyl)propanamido)-5-guanidinopentanoic acid |
| n~2~-[2-({2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]arginine |
| DTXSID60990433 |
| glycylglycyl-l-tyrosyl-l-arginine |
| A14884 |
| D81927 |
| PD133755 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||